Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q59XY0

Entry ID Method Resolution Chain Position Source
AF-Q59XY0-F1 Predicted AlphaFoldDB

No variants for Q59XY0

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for Q59XY0

No associated diseases with Q59XY0

2 regional properties for Q59XY0

Type Name Position InterPro Accession
domain MIF4G-like, type 3 29 - 232 IPR003890
domain Initiation factor eIF-4 gamma, MA3 328 - 460 IPR003891

Functions

Description
EC Number
Subcellular Localization
  • Cytoplasm
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

2 GO annotations of cellular component

Name Definition
catalytic step 2 spliceosome A spliceosomal complex that contains three snRNPs, including U5, bound to a splicing intermediate in which the first catalytic cleavage of the 5' splice site has occurred. The precise subunit composition differs significantly from that of the catalytic step 1, or activated, spliceosome, and includes many proteins in addition to those found in the associated snRNPs.
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.

1 GO annotations of molecular function

Name Definition
RNA binding Binding to an RNA molecule or a portion thereof.

1 GO annotations of biological process

Name Definition
mRNA splicing, via spliceosome The joining together of exons from one or more primary transcripts of messenger RNA (mRNA) and the excision of intron sequences, via a spliceosomal mechanism, so that mRNA consisting only of the joined exons is produced.

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MENSTTTTTT TTVTQPDESY QRTKWIETKK NIKQLLQQLT PSNIKQTVLQ LFQINLLRYQ
70 80 90 100 110 120
GLFIREIMKQ QIRITTNAEL YGSLISIINS KIPEIGELLI NRLVLQFKKN YLQNNKNLIN
130 140 150 160 170 180
SSIIFICQLI NQQVLNEILI LQILQMLLES NVPNNNNNNN NNNIELAIMV LKQTGSYLFK
190 200 210 220 230 240
HSNTALIMIL NRLKDILQDG ANANANGGNG GVGLSSWNRK SIEYILKLAR NDFKNISIIK
250 260 270 280 290 300
NGLDLVETED KETHVITLED KLYSRDHLNV FSVDEEYLDH ENEYIELKKE ILGETDHEDE
310 320 330 340 350 360
NENEIQVIET TKNYEEKITD MSQSELLQYQ KTVYLTIMSS MSSDEAVHKL LKLNFKSKIK
370 380 390 400 410 420
NKTKNKTKTK TNSNDNEILA DMVIKCCSQE KTYSKYYGII GEKLISRNDH WHNLFIKLFK
430 440 450 460 470 480
YYYDIIENFE TNSLRNLGKF FGHLFASDKL ALDQAWSNIK LTEQDTNPAK RILLKFIFQE
490 500 510 520 530 540
MIEELGINEV KERLINDDYL KPYIKGIFPV INVDGKDADA IRFSINFFTA IGLGVLTEEM
550 560 570 580 590 600
RYVLDNLSEP EEEDDRGRSR SRSYSRSASS SSYNSRSRSY SRSQSRSSRS PNPRGRQRFK
610 620 630 640
TKKHNHNESR TPSRENLKRK RSESVTDRNG NNNNNNNNNL QDLLNNLK